PubMed Health⌕ Search

Biomedical subjects

M R Lavin

Publications and source records attributed to M R Lavin.

16 recordsLinked to original sources
PubMed1994

Antiemetic-induced akathisia in cancer patients receiving chemotherapy.

A structured, prospective telephone interview was used to assess the prevalence of akathisia in 24 cancer patients receiving metoclopramide or prochlorperazine during or after chemotherapy. Half of the patients reported subjective motor restlessness, and 75% stated that they would not have informed staff. This report suggests that akathisia is frequently unrecognized in chemotherapy patients receiving metoclopramide and prochlorperazine.

Akathisia, Drug-Induced↗
PubMed1993

Spontaneous hypertensive reactions with monoamine oxidase inhibitors.

Despite long-standing concerns over hypertensive reactions, monoamine oxidase inhibitors (MAOIs) have grown in popularity and are now used in a variety of psychiatric disorders. The risk of hypertensive episodes is less than 1%. This is most likely the result of careful dietary instructions and prudent prescribing of concomitant medications. The possibility exists of spontaneous or unprovoked hypertensive crises in patients receiving MAOIs. In this report, we review the literature on spontaneous hypertensive episodes and present a case report. There has been a total of 11 cases described in six separate reports. We discuss the possible mechanism, risk factors, treatment, and safety of rechallenging the patients with the MAOI. Further research is needed to clarify this reaction. For now, it remains a rare but worrisome phenomenon. It should stand as an additional source of concern for clinicians who are already well aware of the risk of hypertensive episodes in patients receiving MAOIs.

Adult↗
PubMed1993

Diagnosis and pharmacotherapy of conduct disorder.

1. There are few double-blind, placebo-controlled studies of the drug treatment of conduct disorders in children and adolescents. 2. The diagnosis of conduct disorders involves a persistent pattern of behavior in which the basic rights of others and standards of society are violated. 3. There is frequent comorbidity associated with conduct disorders including attention-deficit hyperactivity disorder, oppositional defiant disorder, mood disorders and substance abuse. 4. Childhood Conduct disorder is associated with a significant risk for adult psychopathology. 5. A variety of treatment approaches may be employed to combat conduct disorders. 6. The use of neuroleptics, lithium carbonate, stimulants and other agents is reviewed.

Adolescent↗
PubMed1991

Prophylactic antiparkinson drug use: I. Initial prophylaxis and prevention of extrapyramidal side effects.

The use of prophylactic antiparkinson medications during neuroleptic treatment is controversial. Although the efficacy of these agents in the treatment of extrapyramidal side effects is well established, the questions of when to initiate therapy and for how long remain unanswered. There are only a few double-blind, placebo-controlled studies on the value of concurrent antiparkinson drug use at the beginning of neuroleptic treatment. The authors reviewed all studies on initial prophylaxis, and found most to be methodologically deficient. There is evidence to support the use of these agents to prevent acute dystonic reactions. Further work needs to focus on other types of extrapyramidal symptoms. In light of the inability to predict who will experience these side effects, the authors conclude that initial prophylaxis is beneficial for most patients who are starting neuroleptic medications.

Antiparkinson Agents↗
PubMed1991

Prophylactic antiparkinson drug use: II. Withdrawal after long-term maintenance therapy.

Although the efficacy of long-term neuroleptic treatment of schizophrenic patients is generally accepted, the use of concurrent antiparkinson drugs is less well defined. The value of prolonged antiparkinson drug use in preventing extrapyramidal side effects is controversial. More than 30 studies of antiparkinson drug withdrawal have attempted to answer this question. The authors reviewed all double-blind, placebo-controlled studies, and found most to contain serious methodologic or statistical flaws. There is evidence to support the long-term use of these agents in preventing extrapyramidal side effects. The authors offer an analysis of the benefits and risks that are involved with prophylactic antiparkinson drug use, and conclude that most patients would benefit from maintenance therapy.

Antiparkinson Agents↗